# Study of HS135 in Obese Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

> **NCT06581159** · PHASE1 · TERMINATED · sponsor: **35Pharma Inc** · enrollment: 4 (actual)

## Conditions studied

- Heart Failure With Preserved Ejection Fraction
- Pulmonary Hypertension

## Interventions

- **BIOLOGICAL:** HS135
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06581159
- **Lead sponsor:** 35Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2025-01-23
- **Primary completion:** 2025-07-29
- **Final completion:** 2025-07-29
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Sponsor's Decision
- **Last updated:** 2025-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06581159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06581159, "Study of HS135 in Obese Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06581159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*